Ironwood Pharmaceuticals (IRWD) Competitors $0.75 +0.03 (+3.85%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock IRWD vs. MYGN, ZBIO, RIGL, VSTM, VNDA, EBS, XOMA, CDXS, SGMO, and LXRXShould you be buying Ironwood Pharmaceuticals stock or one of its competitors? The main competitors of Ironwood Pharmaceuticals include Myriad Genetics (MYGN), Zenas Biopharma (ZBIO), Rigel Pharmaceuticals (RIGL), Verastem (VSTM), Vanda Pharmaceuticals (VNDA), Emergent BioSolutions (EBS), XOMA (XOMA), Codexis (CDXS), Sangamo Therapeutics (SGMO), and Lexicon Pharmaceuticals (LXRX). These companies are all part of the "biotechnology" industry. Ironwood Pharmaceuticals vs. Myriad Genetics Zenas Biopharma Rigel Pharmaceuticals Verastem Vanda Pharmaceuticals Emergent BioSolutions XOMA Codexis Sangamo Therapeutics Lexicon Pharmaceuticals Myriad Genetics (NASDAQ:MYGN) and Ironwood Pharmaceuticals (NASDAQ:IRWD) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, community ranking, valuation, media sentiment, earnings, analyst recommendations and profitability. Is MYGN or IRWD more profitable? Ironwood Pharmaceuticals has a net margin of -0.65% compared to Myriad Genetics' net margin of -14.09%. Ironwood Pharmaceuticals' return on equity of -0.96% beat Myriad Genetics' return on equity.Company Net Margins Return on Equity Return on Assets Myriad Genetics-14.09% -4.51% -3.07% Ironwood Pharmaceuticals -0.65%-0.96%0.74% Does the media prefer MYGN or IRWD? In the previous week, Ironwood Pharmaceuticals had 21 more articles in the media than Myriad Genetics. MarketBeat recorded 30 mentions for Ironwood Pharmaceuticals and 9 mentions for Myriad Genetics. Ironwood Pharmaceuticals' average media sentiment score of 0.36 beat Myriad Genetics' score of 0.14 indicating that Ironwood Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Ironwood Pharmaceuticals 6 Very Positive mention(s) 1 Positive mention(s) 12 Neutral mention(s) 5 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend MYGN or IRWD? Myriad Genetics presently has a consensus target price of $20.89, indicating a potential upside of 164.13%. Ironwood Pharmaceuticals has a consensus target price of $4.78, indicating a potential upside of 537.78%. Given Ironwood Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Ironwood Pharmaceuticals is more favorable than Myriad Genetics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Myriad Genetics 3 Sell rating(s) 7 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.19Ironwood Pharmaceuticals 0 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Does the MarketBeat Community prefer MYGN or IRWD? Ironwood Pharmaceuticals received 37 more outperform votes than Myriad Genetics when rated by MarketBeat users. Likewise, 60.76% of users gave Ironwood Pharmaceuticals an outperform vote while only 52.82% of users gave Myriad Genetics an outperform vote. CompanyUnderperformOutperformMyriad GeneticsOutperform Votes47752.82% Underperform Votes42647.18% Ironwood PharmaceuticalsOutperform Votes51460.76% Underperform Votes33239.24% Which has more risk & volatility, MYGN or IRWD? Myriad Genetics has a beta of 1.87, indicating that its stock price is 87% more volatile than the S&P 500. Comparatively, Ironwood Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Do institutionals and insiders hold more shares of MYGN or IRWD? 99.0% of Myriad Genetics shares are held by institutional investors. 2.1% of Myriad Genetics shares are held by company insiders. Comparatively, 12.9% of Ironwood Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has stronger earnings and valuation, MYGN or IRWD? Myriad Genetics has higher revenue and earnings than Ironwood Pharmaceuticals. Ironwood Pharmaceuticals is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMyriad Genetics$837.60M0.87-$263.30M-$1.41-5.61Ironwood Pharmaceuticals$351.41M0.35-$1.00B-$0.03-25.00 SummaryIronwood Pharmaceuticals beats Myriad Genetics on 11 of the 18 factors compared between the two stocks. Remove Ads Get Ironwood Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for IRWD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IRWD vs. The Competition Export to ExcelMetricIronwood PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$121.36M$6.26B$5.29B$7.36BDividend YieldN/A3.24%5.11%4.32%P/E Ratio-25.006.7221.6917.68Price / Sales0.35223.16371.6292.88Price / CashN/A65.6738.1534.64Price / Book-0.345.776.373.94Net Income-$1.00B$142.23M$3.20B$247.45M7 Day Performance-27.18%2.72%1.67%0.48%1 Month Performance-49.66%-14.04%-9.49%-7.08%1 Year Performance-90.49%-12.31%9.59%-0.35% Ironwood Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IRWDIronwood Pharmaceuticals4.5629 of 5 stars$0.75+3.8%$4.78+537.8%-90.7%$121.36M$351.41M-25.00220Analyst DowngradeShort Interest ↓Analyst RevisionNews CoverageGap DownHigh Trading VolumeMYGNMyriad Genetics3.8106 of 5 stars$8.07-0.7%$20.89+158.9%-58.2%$736.86M$837.60M-6.212,700ZBIOZenas BiopharmaN/A$7.75+0.5%$40.00+416.1%N/A$322.27M$5M-2.18N/ANews CoverageGap DownHigh Trading VolumeRIGLRigel Pharmaceuticals2.7678 of 5 stars$17.04-1.2%$36.80+116.0%+48.2%$304.39M$179.28M121.72160News CoveragePositive NewsVSTMVerastem3.0735 of 5 stars$5.10-1.2%$13.88+172.1%-56.5%$262.58M$10M-1.6050VNDAVanda Pharmaceuticals4.1686 of 5 stars$4.19+1.2%$16.50+293.8%+7.6%$244.34M$198.77M-13.09290News CoveragePositive NewsEBSEmergent BioSolutions4.3126 of 5 stars$4.43-1.9%$14.33+223.3%+134.1%$240.88M$1.01B-1.082,420Positive NewsXOMAXOMA4.3661 of 5 stars$19.23-1.1%$72.00+274.4%-14.5%$230.36M$10.22M-5.5310Gap UpCDXSCodexis3.1454 of 5 stars$2.06-3.3%$8.33+304.5%-16.4%$170.64M$59.35M-2.37250Gap DownSGMOSangamo Therapeutics2.2007 of 5 stars$0.71+7.7%$5.17+630.9%+33.0%$158.85M$57.80M-0.94480Gap DownHigh Trading VolumeLXRXLexicon Pharmaceuticals2.8166 of 5 stars$0.52+23.5%$3.67+608.7%-72.6%$127.40M$31.08M-0.69140Analyst ForecastHigh Trading Volume Remove Ads Related Companies and Tools Related Companies Myriad Genetics Alternatives Zenas Biopharma Alternatives Rigel Pharmaceuticals Alternatives Verastem Alternatives Vanda Pharmaceuticals Alternatives Emergent BioSolutions Alternatives XOMA Alternatives Codexis Alternatives Sangamo Therapeutics Alternatives Lexicon Pharmaceuticals Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IRWD) was last updated on 4/16/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredMarkets in Chaos? Here’s What to Do.Wall Street's on edge with tariffs. And volatility? It's not slowing down. You've seen the headlines… Bu...Investors Alley | SponsoredCatastrophicThe losses are catastrophic... $760 billion wiped off the Magnificent 7, in a single day.InvestorPlace | SponsoredTrump 2028 could be a “bonanza” for investorsAs you may have heard, Donald Trump is planning to run for a THIRD term in 2028. Recently he told NBC news ...Paradigm Press | SponsoredIf Gold Is ‘Stalling,’ Why Are Banks Hoarding Billions In Secret?Prosperity was something every American family could build, protect, and pass down. Because that's what legacy...Colonial Metals | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredCould this be my downfall?I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ironwood Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ironwood Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy IRWD Stock Free IRWD Stock Alerts